reductions were not associated with an increased risk of progression. Bone metastasis is very common in metastatic or locally advanced breast cancer. Since the authorisation for first-line use (PALOMA-2) it has become a standard of treatment for metastatic or locally advanced breast cancer.

REFERENCES AND/OR ACKNOWLEDGEMENTS

Conflict of interest No conflict of interest

5PSQ-164 REAL SAFETY OF DARATUMUMAB IN MYELOMA MULTIPLE
MC Sánchez Argaiz*, M Valera Rubio, N Martínez Casanova, B Cancela Diez. Hospital Virgen De La Victoria, Hospital Pharmacy, Málaga, Spain
10.1136/ehjpharm-2021-eahpconf.283

Background and importance The overall survival of patients with multiple myeloma (MM) has changed dramatically in the last decade. Immunotherapy has emerged as a promising treatment, such as daratumumab. This human monoclonal IgG kappa antibody that targets CD38 is used in monotherapy or in combination, and has demonstrated durable responses. But good clinical management of toxicities is needed to reach the goal of therapy.

Aim and objectives To assess the safety of daratumumab in monotherapy and in combination with other agents used in our institution, and to review the clinical management of toxicities.

Material and methods A retrospective observational study was conducted in a second level hospital. We reviewed the medical records of all patients diagnosed with MM who received at least one cycle of daratumumab as monotherapy or as combination therapy in our hospital until August 2020. Collected data were: sex, age, cytogenetic risk, prior line of therapy, prior autologous stem cell transplantation (ASCT), daratumumab monotherapy or combination therapy, adverse drug reactions (ADRs), grade and clinical management (supportive treatments, temporary interruptions and permanent discontinuations).

Results 33 patients received at least one cycle of daratumumab and were included (26% men). Median age was 64 (42–77) years, 26% (8) had high cytogenetic risk abnormalities, median number of prior lines of therapy was 2 (0–6) and 74% (23) of patients received daratumumab in combination therapy. Average number of cycles received was 8 (1–38). 39% (13) of patients had infusion reactions (IRs) but the majority (92%) occurred during the first infusion and were grades 1–2. We registered 22 haematological severe ADRs (grades 3–4) and the most common was thrombocytopenia (60%), followed by neutropenia (22%), all requiring supportive treatment, and in 32% temporary interruption of treatment was necessary. 28 non-haematological severe ADRs (grades 3–4) were registered, 50% were severe infections, most of them respiratory that required temporary interruption to therapy, and 10 (71%) needed hospital admission. Almost one in three patients experienced permanent discontinuation of daratumumab related to toxicity (90% receiving combination therapy).

Conclusion and relevance Most adverse reactions related to daratumumab therapy were clinically manageable, but the incidence of severe haematological toxicity and severe respiratory infections makes close monitoring of side effects necessary, along with practical management strategies to reach the maximal benefit.

REFERENCES AND/OR ACKNOWLEDGEMENTS

Conflict of interest No conflict of interest

5PSQ-165 INCIDENCE AND MANAGEMENT OF ETOPOSIDE HYPERSENSITIVITY IN PAEDIATRIC PATIENTS
N Báez Gutiérrez, H Rodríguez Ramallo*, C Álvarez Del Vayo Benito, B Fernández Rubio. Virgen Del Rocío University Hospital, Pharmacy, Seville, Spain
10.1136/ehjpharm-2021-eahpconf.284

Background and importance Etoposide is widely used in paediatric chemotherapy treatment, although hypersensitivity can be severe and treatment limiting. There are conflicting data in the literature regarding the incidence of etoposide hypersensitivity reactions in adults and children. Reported rates of hypersensitivity range from 2% to 51%.

Aim and objectives The aim of this study was to assess the incidence of etoposide hypersensitivity and to evaluate potential risk factors for hypersensitivity in paediatric patients in a third level hospital.

Material and methods A retrospective observational study was conducted in paediatric patients treated with etoposide from June 2013 to September 2020. Data collected were: demographics (age, sex), diagnosis, dose, infusion rate, infusion concentration, symptoms of hypersensitivity, CTCAE grade of hypersensitivity reaction and management of hypersensitivity reaction. Data were collected from the electronic medical records and pharmacy records.

Results 213 patients were treated with etoposide during the period of the study. Mean age was 6.73 (range 0.16–17) years and 58.68% were male. Indications for etoposide were lymphocytic acute leukaemia 20.18%; neuroblastoma 16.9%; Ewing’s sarcoma 16.9%; Hodgkin’s lymphoma 11.27%; myeloid acute leukaemia 8.9%; and other 25.82%. Doses administered ranged from 200 to 100 mg/m2 and from 2.5 to 6 mg/kg. Median infusion rate was 55 (2–200) mg/hour. Median infusion concentration was 0.3 (0.2–0.5) mg/mL. Hypersensitivity reactions occurred in 23 (10.8%) patients; 3 and 20 cases were classified as grade I and grade II of the CTCAE, respectively. Symptoms of hypersensitivity were lip cyanosis (n=7), pruritus (n=7), flushing (n=7), nausea (n=5), cutaneous rash (n=5), cough (n=4), rhinoconjunctivitis (n=1), hypertension (n=1), shortness of breath (n=1), abdominal pain (n=1), facial paraesthesia (n=1), fever (n=1) and angioedema (n=1). All hypersensitivity reactions were successfully managed with medication (corticoids and antihistamines). Subsequent doses were administered with premedication and reduction of the infusion rate. We did not observe any statistically significant associations between the variables collected and the appearance of hypersensitivity reactions.

Conclusion and relevance The incidence of hypersensitivity reactions was moderate, affecting approximately 10% of patients. All hypersensitivity reactions were mild and were resolved by standard treatment. We were unable to establish if any of the variables collected were risk factors for hypersensitivity reactions, probably due to the small sample size derived from the rarity of the event. Other studies have observed a relationship between the rate of infusion and the concentration of etoposide.